modelFusidicAcid
Extends from Pharmacolibrary.Drugs.ATC.J.J01XC01.
Information
| name: | FusidicAcid | |
| ATC code: | J01XC01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 11 | L |
| clearance: | 0.082 | L/h/kg |
| other parameters in model implementation | ||
Fusidic acid is a steroidal antibiotic primarily used for the treatment of infections caused by Staphylococcus species, particularly methicillin-resistant Staphylococcus aureus (MRSA). It is available in oral and topical formulations and is used most commonly in skin, soft tissue, and bone infections. Fusidic acid is still approved for clinical use in several countries.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of fusidic acid.
References
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)